1642  
Box 509

24024

PATENT TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this TRANSMITTAL is being deposited with the U.S. Postal Service, with sufficient postage, as first class mail in an envelope addressed to the U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, Virginia 22202, on this 9<sup>th</sup> day of April, 2003.

Typed or Printed name of person signing this certificate:  
Wendy A. Frick

Signed: Wendy A. Frick

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	)	Examiner: Ungar, Susan
Montano, et al.	)	
	)	
Serial No.: 09/972,758	)	Art Unit: 1642
	)	
Filed: October 5, 2001	)	
	)	
For: <b>SUPPRESSORS OF HUMAN BREAST CANCER CELL GROWTH</b>	)	Attorney Docket No.: 27708/04004
	)	

U.S. Patent and Trademark Office  
Box Sequence  
P.O. Box 2327  
Arlington, Virginia 22202

## TRANSMITTAL OF STATEMENT REGARDING SEQUENCE LISTING

Sir:

Transmitted herewith are the following:

1. Statement Regarding Sequence Listing;
2. Paper Copy of Sequence Listing;
3. A Computer Readable Form (CRF) of the Sequence Listing;
4. A copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures; and
5. A Return Receipt Postcard.


It is believed that no further fee is required relating to the filing of this Statement. If this is not the case, the Patent Office is hereby authorized to charge any related fee to Deposit Account No. 03-0172. A duplicate copy of this sheet is attached.

Respectfully submitted,

Date: April 9, 2003

By: Pamela A. Docherty  
Pamela A. Docherty, Reg. No. 40,591  
(216) 622-8416

RECEIVED  
APR 16 2003  
TECH CENTER 1600/2900



24024

PATENT TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this STATEMENT is being deposited with the U.S. Postal Service, with sufficient postage, as first class mail in an envelope addressed to the U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, Virginia 22202, on this 9<sup>th</sup> day of April, 2003.

Typed or Printed name of person signing this certificate:

Wendy A. Frick

Signed: Wendy A. Frick

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	)	Examiner: Ungar, Susan
Montano, et al.	)	
	)	
Serial No.: 09/972,758	)	Art Unit: 1642
	)	
Filed: October 5, 2001	)	
	)	
For: <b>SUPPRESSORS OF HUMAN BREAST CANCER CELL GROWTH</b>	)	Attorney Docket No.: 27708/04004
	)	

U.S. Patent and Trademark Office  
Box Sequence  
P.O. Box 2327  
Arlington, Virginia 22202

## STATEMENT REGARDING SEQUENCE LISTING

Dear Sir:

In response to the Office communication mailed on December 31, 2002, Applicant submits herewith a paper copy of a Sequence Listing as required by 37 C.F.R. 1.821(c), a copy of the same Sequence Listing in computer readable form as required by 37 C.F.R. 1.821(e), and a copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures received from the Patent Office. The content of the paper copy and the computer readable copy of the Sequence Listing are the same. The sequences in the Sequence Listing are the same as the sequences in the text and the figures of the application as filed. Accordingly, the Sequence Listing adds no new matter.

TECH CENTER 1600/2900

APR 16 2003

RECEIVED

Applicants respectfully request entry of the Sequence Listing into the case.

Respectfully submitted,

Dated: April 9, 2003

Pamela A. Docherty  
Pamela A. Docherty, Reg. No. 40,561  
(216) 622-8416

APR 14 2003

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- 7.

**RECEIVED**

Other: \_\_\_\_\_

APR 16 2003

**Applicant must provide:**

TECH CENTER 1600/2900

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123

For CRF submission help, call (703) 308-4212

For PatentIn software help, call (703) 557-0400

Please return a copy of this notice with your response.